Von Hoff D - Search Results

1

Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth.

Yang L, TeSlaa T, Ng S, Nofal M, Wang L, Lan T, Zeng X, Cowan A, McBride M, Lu W, Davidson S, Liang G, Oh TG, Downes M, Evans R, Von Hoff D, Guo JY, Han H, Rabinowitz JD. Yang L, et al. Among authors: von hoff d. Med. 2022 Feb 11;3(2):119-136. doi: 10.1016/j.medj.2021.12.008. Med. 2022. PMID: 35425930 Free PMC article.

2

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Han H, et al. Among authors: von hoff dd. Cancer Res. 2002 May 15;62(10):2890-6. Cancer Res. 2002. PMID: 12019169

3

Targeting Aurora-2 kinase in cancer.

Warner SL, Bearss DJ, Han H, Von Hoff DD. Warner SL, et al. Among authors: von hoff dd. Mol Cancer Ther. 2003 Jun;2(6):589-95. Mol Cancer Ther. 2003. PMID: 12813139 Review.

4

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ. Rojanala S, et al. Among authors: von hoff dd. Mol Cancer Ther. 2004 Apr;3(4):451-7. Mol Cancer Ther. 2004. PMID: 15078988

5

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.

Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. Gray PJ Jr, et al. Among authors: von hoff dd. Mol Cancer Ther. 2004 May;3(5):641-6. Mol Cancer Ther. 2004. PMID: 15141022

6

PRL phosphatases as potential molecular targets in cancer.

Stephens BJ, Han H, Gokhale V, Von Hoff DD. Stephens BJ, et al. Among authors: von hoff dd. Mol Cancer Ther. 2005 Nov;4(11):1653-61. doi: 10.1158/1535-7163.MCT-05-0248. Mol Cancer Ther. 2005. PMID: 16275986 Review.

7

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD. Wang H, et al. Among authors: von hoff dd. Semin Oncol. 2006 Aug;33(4):513-20. doi: 10.1053/j.seminoncol.2006.04.013. Semin Oncol. 2006. PMID: 16890805 Review.

8

Aurora sheds light on head and neck squamous cell carcinoma.

Han H, Von Hoff DD. Han H, et al. Among authors: von hoff dd. Clin Cancer Res. 2006 Sep 1;12(17):5003-4. doi: 10.1158/1078-0432.CCR-06-1329. Clin Cancer Res. 2006. PMID: 16951211 Review. No abstract available.

9

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

Wang H, Han H, Von Hoff DD. Wang H, et al. Among authors: von hoff dd. Cancer Res. 2006 Oct 1;66(19):9722-30. doi: 10.1158/0008-5472.CAN-05-4602. Cancer Res. 2006. PMID: 17018631

10

Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.

Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H. Warner SL, et al. Among authors: von hoff dd. Mol Cancer Ther. 2006 Oct;5(10):2450-8. doi: 10.1158/1535-7163.MCT-06-0202. Mol Cancer Ther. 2006. PMID: 17041088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

776 results

Search Page